13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)

Page 3 of 9 – SEC Filing

CUSIP No. 253031108

1

Names of Reporting Persons.

 

Peter Kolchinsky

2 Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ¨
(b) ¨
3 SEC Use Only
4

Source of Funds (See Instructions):

AF

5

Check if disclosure of legal proceedings
is required pursuant to Items 2(d) or 2(e):

¨

6

Citizenship or Place of Organization.
United States

Number

of Shares

Beneficially

Owned by

Each

Reporting

Person With

7

Sole Voting Power    0
shares

8

Shared Voting Power    4,588,536
shares

9

Sole Dispositive Power
   0 shares

10

Shared
Dispositive Power    4,588,536 shares

11

Aggregate Amount Beneficially Owned by
Each Reporting Person

4,588,536 shares

12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)     ¨
13

Percent of Class Represented by Amount
in Row (11)

20.81%2

14

Type of Reporting Person (See Instructions)

HC, IN

2
Represents 2,428,571 shares of the common stock (“Common Stock”) of Dicerna Pharmaceuticals, Inc. (the
“Issuer”) and 2,159,965 shares of the Common Stock underlying the Preferred Stock (as defined below) which
constitute approximately 20.81% of the class outstanding. The percentage calculation assumes that there are currently
20,794,193 outstanding shares of the Common Stock of the Issuer, based on the Issuer’s Form 10-K as filed with the
Securities and Exchange Commission (“SEC”) on March 30, 2017.

Follow Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)